MedPath

A phase I study of combination adjuvant immunotherapy for patients with resectable hepatocellular carcinoma

Phase 1
Conditions
hepatocellular carcinoma
Registration Number
JPRN-UMIN000029991
Lead Sponsor
Yamaguchi University Graduate School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

Uncontroled general complication. etc

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
safety
Secondary Outcome Measures
NameTimeMethod
1)specific CTL response in PBMC 2)specific CTL response in the tumor 3)relapse-free survival 4)overall survival
© Copyright 2025. All Rights Reserved by MedPath